Genentech gains US OK for Actemra SC
This article was originally published in Scrip
Executive Summary
Genentech gained the FDA's approval on 21 October to market a subcutaneous formulation of Actemra (tocilizumab) as a treatment for adults with moderate-to-severe rheumatoid arthritis (RA) who have used one or more disease-modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX), which did not provide enough relief – making it the sixth indication approved in the US in four years for the medicine.